| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236962 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(7 years from now) | |
| US10414751 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(12 years from now) | |
| US9840492 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8754227 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(7 years from now) | |
| US11247981 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
May, 2033
(9 years from now) | |
Vivjoa is owned by Mycovia Pharms.
Vivjoa contains Oteseconazole.
Vivjoa has a total of 5 drug patents out of which 0 drug patents have expired.
Vivjoa was authorised for market use on 26 April, 2022.
Vivjoa is available in capsule;oral dosage forms.
Vivjoa can be used as vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential.
Drug patent challenges can be filed against Vivjoa from 2031-04-27.
The generics of Vivjoa are possible to be released after 17 March, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 26, 2027 |
| Generating Antibiotic Incentives Now (GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 2031-04-27
Market Authorisation Date: 26 April, 2022
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential
Dosage: CAPSULE;ORAL
VIVJOA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic